Janney Montgomery Scott Starts Recro Pharma (REPH) at Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Janney Montgomery Scott initiated coverage on Recro Pharma (NASDAQ: REPH) with a Buy rating and a price target of $21.00.
Shares of Recro Pharma closed at $9.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Starts Micron Technology (MU) at Buy
- MoffettNathanson Downgrades AMC Networks (AMCX) to Sell
- Credit Suisse Downgrades NetApp (NTAP) to Underperform
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesJanney Montgomery Scott
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!